Breast cancer, a disease that threatens the health of countless women, brings immense suffering to both patients and their families. Eribulin Mesylate Injection is an important medication for treating locally advanced or metastatic breast cancer, carrying great hope and expectation. October 25 also coincides with “Love Your Breasts Day,” symbolizing that Eribulin will provide high-quality solutions to safeguard women's health.

Eribulin has a complex structure, multiple synthesis steps, challenging manufacturing processes, and intricate quality control, earning it the title of the “Mount Everest” of the pharmaceutical industry. On June 28, Kvvit’s Eribulin Mesylate Injection received approval from the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic breast cancer patients who have previously received at least two chemotherapy regimens (including anthracyclines and taxanes). Kvvit becomes the second global and first Chinese pharmaceutical company to receive FDA ANDA approval for this product.

At the shipment ceremony, Mr. Wei Dong, Vice President of Qingfeng Kvvit, stated that Kvvit’s approval of this “Mount Everest-like” project was made possible by the rapid development of China’s pharmaceutical industry over the past decade and the strong support from partners , and the raw materials supply team. The approval of this project is a result of Kvvit’s unwavering strategic focus, perseverance in doing the right thing, and fully demonstrates the company’s determination, dedication, and relentless efforts.

As Mr. Wei Dong, Vice President of Qingfeng Kvvit, announced the official “departure” of the shipment, Ibrutinib Mesylate Injection began its journey to the United States, marking the start of its global expansion.